With positive phase IIa data for ENV-101 in idiopathic pulmonary fibrosis (IPF) in hand, showing some lung damage was reversed, Endeavor Biomedicines Inc. said it’s ready to begin further phase II studies in the indication.
A new deal between privately held Hummingbird Bioscience Pte. Ltd. and Endeavor Biomedicines Inc. is just one of three antibody-drug conjugate (ADC) agreements reached in the past week, marking a fourth-quarter surge for the therapy.
GSK plc is the latest pharma giant to bite the “magic bullet” of antibody-drug conjugate (ADC) drugs, promising to pay the Chinese immunotherapy developer Hansoh Pharmaceutical Co. Ltd. $85 million up front and over $1.4 billion in milestone payments in a licensing deal for HS-20089.
GSK plc is the latest pharma giant to bite the “magic bullet” of antibody-drug conjugate (ADC) drugs, promising to pay the Chinese immunotherapy developer Hansoh Pharmaceutical Co. Ltd. $85 million up front and over $1.4 billion in milestone payments in a licensing deal for HS-20089.
A new deal between privately held Hummingbird Bioscience Pte. Ltd. and Endeavor Biomedicines Inc. is just one of three antibody-drug conjugate (ADC) agreements reached in the past week, marking a fourth-quarter surge for the therapy. Endeavor has acquired the exclusive, worldwide rights to Hummingbird’s HMBD-501, a HER3-targeted ADC with an exatecan payload. Hummingbird could receive up-front and milestone payments of up to $430 million, along with royalties from net sales.
Endeavor Biomedicines Inc.’s $101 million series B round will let the firm forge ahead with ENV-101 (taladegib), a small-molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway, for cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, described as a potentially best-in-class small-molecule inhibitor of ULK1/2 in KRAS-driven cancers.
San Diego area startup Endeavor Biomedicines Inc. launched in January 2021, with a $62 million series A financing from Omega Funds, Longitude Capital and its own management team. The company is working on one asset, ENV-101 or taladegib, a small-molecule inhibitor targeting the Hedgehog pathway, which it plans to develop for the treatment of idiopathic pulmonary fibrosis (IPF).
